Patents Examined by George C. Elliott
  • Patent number: 6124272
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PDK-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PDK-1. Methods of using these compounds for modulation of PDK-1 expression and for treatment of diseases associated with expression of PDK-1 are provided.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: September 26, 2000
    Assignee: Isis Pharmaceutical Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Patent number: 6120998
    Abstract: Endo-xyloglucan transferases responsible for growth of plant cell wall, genes coding for the enzymes, a method of transferring xyloglucan molecules by using the enzyme, and methods of using the gene are described.
    Type: Grant
    Filed: March 31, 1998
    Date of Patent: September 19, 2000
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Kazuhiko Nishitani, Kazuhide Okazawa, Kiyozo Asada, Ikunoshin Kato
  • Patent number: 6121047
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SHP-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SHP-1. Methods of using these compounds for modulation of SHP-1 expression and for treatment of diseases associated with expression of SHP-1 are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: September 19, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6117852
    Abstract: The present invention discloses a boron-containing pharmaceutical composition useful in boron neutron capture therapy of hepatoma, which includes lipiodol, stibmicron boron powder, lecithin and unsaturated fatty acid. The lipiodol has a property of a high retention in hepatoma, the lecithin has a boron carrying capacity, and the unsaturated fatty acid has a function of rendering lecithin soluble in lipiodol.
    Type: Grant
    Filed: December 29, 1997
    Date of Patent: September 12, 2000
    Assignee: National Science Council
    Inventor: Fong-In Chou
  • Patent number: 6114517
    Abstract: Methods are provided for inhibiting the expression of cell adhesion molecules using inhibitors of signaling molecules involved in human TNF-.alpha. signaling. These inhibitors include monoclonal antibodies, peptide fragments, small molecule inhibitors, and, preferably, antisense oligonucleotides. Methods for treatment of diseases, particularly inflammatory and immune diseases, associated with overexpression of cell adhesion molecules are provided.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: September 5, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Xiaoxing S. Xu
  • Patent number: 6114152
    Abstract: Nucleic acids are made by adding a known nucleotide sequence to the 3' end of a first RNA having a known sequence at the 5' end to form a second RNA and reverse transcribing the second RNA to form a cDNA. In one embodiment, the first RNA is an amplified mRNA, the known sequence at the 5' end comprises a poly(T) sequence, the adding step comprises using a polyadenyltransferase to add a poly(A) sequence to the 3' end, the reverse transcribing step is initiated at a duplex region comprising the poly(T) sequence hybridized to the poly(A) sequence, the cDNA is converted to double-stranded cDNA by a polymerase initiating from a noncovalently joined duplex region, and the double-stranded cDNA is transcribed to form one or more third RNAs.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: September 5, 2000
    Assignee: The Regents of the University of California
    Inventors: Tito Serafini, Percy Luu, John Ngai, David Lin
  • Patent number: 6110740
    Abstract: A polynucleotide encoding a human vault-associated vRNA or its complementary strand. A purified and isolated polynucleotide molecule consisting essentially of a human vault RNA, or its complementary strands, or a combination of a nucleotide sequence consisting essentially of a human vault RNA and its complementary strands. A method of diagnosing a patient with a multidrug-resistant cancer. A method of treating a patient with multidrug-resistant cancer. A composition for treating multidrug-resistant cancer comprising a polynucleotide which hybridizes with a human vault-associated vRNA. A method of screening for compositions for treating a patient with multidrug-resistant cancer.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: August 29, 2000
    Assignee: Regents of the University of California
    Inventors: Leonard H. Rome, Valerie A. Kickhoefer
  • Patent number: 6110736
    Abstract: DNA constructs and methods for conducting site-specific recombination in plants is described. The method utilizes FLP recombinase to excise a region of DNA flanked by a pair of directly repeated site-specific recombination sequences which are capable of interacting with a FLP recombinase.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: August 29, 2000
    Assignee: Purdue Research Foundation
    Inventors: Thomas K. Hodges, Leszek A. Lyznik
  • Patent number: 6110462
    Abstract: The present invention discloses catalytic or enzymatic DNA molecules that contain a modified nucleotide and that are capable of cleaving nucleic acid sequences or molecules, particularly RNA, in a site-specific manner, as well as compositions including same. Methods of making and using the disclosed enzymes and compositions are also disclosed.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: August 29, 2000
    Assignee: The Scripps Research Institute
    Inventors: Carlos F. Barbas, Gerald Joyce, Stephen W. Santoro, Sakthivel Kandasamy
  • Patent number: 6107092
    Abstract: Antisense compounds, compositions and methods are provided for modulating the function or amount of SRA. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to SRA or nucleic acids encoding SRA. Methods of using these compounds for modulation of SRA levels and for treatment of diseases associated with SRA are provided.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: August 22, 2000
    Assignees: Isis Pharmaceuticals Inc., Baylor College of Medicine
    Inventors: Lex M. Cowsert, C. Frank Bennett, Bert W. O'Malley
  • Patent number: 6107479
    Abstract: The present invention relates to a process for the preparation of an oligomeric compound, comprising introduction of a lipophilic capping group to an unreacted reactive group, suitable for chain elongation, of a not elongated oligomeric compound intended to be elongated in a preceeding chain-elongation step, by reacting a lipophilic capping compound with said unreacted reactive group, which lipophilic capping group is not removable under the applied conditions of the synthesis and work-up of the oligomeric compound; and which not elongated oligomeric compound capped with said lipophilic capping group can be separated from said oligomeric compound on a hydrophobic stationary phase.
    Type: Grant
    Filed: May 6, 1999
    Date of Patent: August 22, 2000
    Assignee: Novartis AG
    Inventors: Fran.cedilla.ois Natt, Robert Haner
  • Patent number: 6107041
    Abstract: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.
    Type: Grant
    Filed: December 16, 1998
    Date of Patent: August 22, 2000
    Assignee: Apoptogen, Inc.
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Peter Liston, Stephen Baird, Benjamin K. Tsang, Christine Pratt
  • Patent number: 6107478
    Abstract: A retroviral vector comprising a retrovirus with infectivity for birds and/or mammals in which at least part of the genomic RNA sequences carrying information for the production of viral proteins required in trans for retroviral replication have been replaced by one or more sequences carrying information to be introduced in a target cell chromosome, characterized in that the primer binding site (PBS) has been modified to a sequence that does not allow strong base pairing with the 3' end or other priming sequence in any naturally occurring tRNA. The present application is directed to the tRNA-like primer.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: August 22, 2000
    Inventors: Finn Skou Pedersen, Anders Henrik Lund, Jette Lovmand, Poul J.o slashed.rgensen, Mogens Duch
  • Patent number: 6107094
    Abstract: Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein "ds" indicates the RNase's specificity for certain double-stranded RNA substrates.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: August 22, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Patent number: 6107063
    Abstract: The invention relates to processes for the microbial production of L-isoleucine. To this end, in a gene in vitro of a threonine dehydratse, one or more bases in the gene region coding the enzyme's allosteric domains are exchanged in such a way that at least one amino acid in the amino acid sequence of the allosteric domains of the enzyme is replaced by another so that the enzyme is no longer inhibited by L-isoleucine feedback. Furthermore, concrete amino acid exchanges in the amino acid sequence of the enzyme are effected in a gene in vitro of a threonin dehydratase of Corynebacterium glutamicum by base exchange both outside and inside and outside the gene region coding the allosteric domains of the enzyme si that, after the transformation of such mutated threonine dehydratase genes into a threonine or L-isoleucine-producing host cell, the latter repeatedly forms L-isoleucine.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: August 22, 2000
    Assignee: Forschungszentrum Juelich GmbH
    Inventors: Bettina Moeckel, Lothar Eggeling, Hermann Sahm
  • Patent number: 6099832
    Abstract: A method is provided for forming a graft in heart tissue which comprises the transplantation of cells chosen from cardiomyocytes, fibroblasts, smooth muscle cells, endothelial cells and skeletal myoblasts. The grafts are especially useful in treating scar tissue on the heart.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: August 8, 2000
    Assignee: Genzyme Corporation
    Inventors: Donald A. G. Mickle, Ren-Ke Li, Richard D. Weisel
  • Patent number: 6099823
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: August 8, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Dean A. Falb
  • Patent number: 6100090
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3K p85. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3K p85. Methods of using these compounds for modulation of PI3K p85 expression and for treatment of diseases associated with expression of PI3K p85 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: August 8, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Patent number: 6096720
    Abstract: A pharmaceutical composition comprising (A) an oligonucleotide 8 to 50 nucleotides in length, which is targeted to mRNA encoding human raf and is capable of inhibiting raf expression, entrapped in (B) sterically stabilized liposomes.
    Type: Grant
    Filed: April 23, 1998
    Date of Patent: August 1, 2000
    Assignee: Novartis AG
    Inventors: William Guy Love, Paul Leslie Nicklin, Karen Ophelia Hamilton, Judith Ann Phillips
  • Patent number: 6096722
    Abstract: Compositions and methods are provided for the modulation of expression of cellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. Methods of modulating expression of cellular adhesion molecules are provided, as are methods of treating conditions associated with cellular adhesion molecules. In a preferred embodiment, the cellular adhesion molecule is ICAM-1, and a preferred antisense sequence targeted to human ICAM-1 is demonstrated to have clinical utility in several disease indications.
    Type: Grant
    Filed: May 27, 1998
    Date of Patent: August 1, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Christopher K. Mirabelli, Brenda Baker